LY266097, >=98% (HPLC), powder

Biochem/physiol Actions

LY266097 is a selective 5HT-2B antagonist with a pKI of 9.7 for the human cloned 5-HT2B receptor and a 100-fold greater selectivity for 5-HT2B than the human 5-HT2C and 5-HT2A.

Features and Benefits

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573445 LY266097, >=98% (HPLC), powder white to tan 100 KPXKZZURYAXZQE-UHFFFAOYSA-N 1S/C21H23ClN2O2.ClH/c1-12-4-6-16-15(10-12)14-8-9-23-17(20(14)24-16)11-13-5-7-18(25-2)21(26-3)19(13)22;/h4-7,10,17,23-24H,8-9,11H2,1-3H3;1H
£635.14 (exc VAT) per 25MG
-
+
3573446 LY266097, >=98% (HPLC), powder white to tan 100 KPXKZZURYAXZQE-UHFFFAOYSA-N 1S/C21H23ClN2O2.ClH/c1-12-4-6-16-15(10-12)14-8-9-23-17(20(14)24-16)11-13-5-7-18(25-2)21(26-3)19(13)22;/h4-7,10,17,23-24H,8-9,11H2,1-3H3;1H
£181.07 (exc VAT) per 5MG
-
+